Study sheds light on treating cancer
Using light to target and kill cancer cells alternatively without surgery
A new study, affiliated with UNIST has presented a natural, alternative, and holistic cancer treatment that uses light to selectively wipe out cancerous cells without harming surrounding tissue. With further research, this novel method might eventually be used to treat tumors in humans.
This study was jointly conducted by Prof. Tae-Hyuk Kwon (School Natural Science), Prof. Mi Hee Lim (School of Natural Science), and Prof. Hyun-Woo Rhee (School of Natural Science), and eight other researchers at UNIST.
In the study, the team developed photodynamic therapy (PDT) agent composed of Ir(III) complexes for cancer cells via a molecular design strategy for efficient ROS generation that accounted for appropriate energy levels and high emission quantum yields.
The team expects that their Ir(III) complexes could be used for additive-free photo-cross-linking in other fields beyound PDT.
Original publication
Jung Seung Nam, Myeong-Gyun Kang, Juhye Kang, Sun-Young Park, Shin Jung C. Lee, Hyun-Tak Kim, Jeong Kon Seo, Oh-Hoon Kwon, Mi Hee Lim, Hyun-Woo Rhee, and Tae-Hyuk Kwon; "Endoplasmic Reticulum-Localized Iridium(III) Complexes as Efficient Photodynamic Therapy Agents via Protein Modifications"; JACS; 2016
Original publication
Jung Seung Nam, Myeong-Gyun Kang, Juhye Kang, Sun-Young Park, Shin Jung C. Lee, Hyun-Tak Kim, Jeong Kon Seo, Oh-Hoon Kwon, Mi Hee Lim, Hyun-Woo Rhee, and Tae-Hyuk Kwon; "Endoplasmic Reticulum-Localized Iridium(III) Complexes as Efficient Photodynamic Therapy Agents via Protein Modifications"; JACS; 2016
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Taconic Biosciences and Cellaria Biosciences collaborate to facilitate xenograft use in oncology research

Protein mingling under blue light
Global Pharmaceutical companies expect hard price competition in the rising Biosimilars segment - Bi-annual survey among more than 80 executives from globally active pharmaceutical companies based in 16 countries and spread over four continents
Centre Léon Bérard - Lyon, France
Killer silk: Making silk fibers that kill anthrax and other microbes in minutes

Brooks Instrument GmbH - Dresden, Germany
"Allergy cells" can aggravate cancer and psoriasis
Halcygen to acquire wholly owned subsidiary of Hospira
